Gene Therapy Promising for Cerebral Adrenoleukodystrophy but Carries Risk of Blood Cancer
source: shutterstock.com

Gene Therapy Promising for Cerebral Adrenoleukodystrophy but Carries Risk of Blood Cancer

The use of the gene therapy elivaldogene autotemcel (Skysona), has been approved due to its success in the treatment of patients diagnosed with the neurological disease cerebral adrenoleukodystrophy (CALD). The…

Continue Reading Gene Therapy Promising for Cerebral Adrenoleukodystrophy but Carries Risk of Blood Cancer

Positive Trial Data is Welcomed News for Spinal Muscular Atrophy Patients

Spinal muscular atrophy (SMA) is a rare disease causing progressive muscular weakness. Severe forms of the disease can be fatal to infants. Apitegromab is an experimental therapy that was successful…

Continue Reading Positive Trial Data is Welcomed News for Spinal Muscular Atrophy Patients
An Unexpected Liver Transplant – Part Two
source: shutterstock.com

An Unexpected Liver Transplant – Part Two

Written by Bill Clark Part 2 - Our Journey from Liver Failure to Transplant Continued from Part 1 “A new liver.” That was Becky’s answer pretty much every morning from…

Continue Reading An Unexpected Liver Transplant – Part Two
It Took Almost 60 Years for the Correct Diagnosis and Treatment for Primary Immunodeficiency
Bru-nO / Pixabay

It Took Almost 60 Years for the Correct Diagnosis and Treatment for Primary Immunodeficiency

Eighty-five-year-old Frank Meuers considers his 500th immunoglobulin infusion to be a cause for celebration. Frank has logged details of his doctor’s visits since his first dose of replacement therapy with…

Continue Reading It Took Almost 60 Years for the Correct Diagnosis and Treatment for Primary Immunodeficiency
Reducing the Itch: Life with Progressive Familial Intrahepatic Cholestasis (PFIC)
source: unsplash.com

Reducing the Itch: Life with Progressive Familial Intrahepatic Cholestasis (PFIC)

Acknowledgment: This patient story is sponsored by Ipsen Biopharmaceuticals, Inc. and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing…

Continue Reading Reducing the Itch: Life with Progressive Familial Intrahepatic Cholestasis (PFIC)
Alzheimer’s: Researchers at Japan’s Riken Center Discover a New Treatment to Alleviate Symptoms and Improve Memory
Kapa65 / Pixabay

Alzheimer’s: Researchers at Japan’s Riken Center Discover a New Treatment to Alleviate Symptoms and Improve Memory

The Riken Center team, headed by Dr. Takaomi Saido and using mice with Alzheimer’s, discovered that dopamine may lessen the brain’s physical symptoms and improve memory. The study, featured in…

Continue Reading Alzheimer’s: Researchers at Japan’s Riken Center Discover a New Treatment to Alleviate Symptoms and Improve Memory
Investigational Therapy Earns Orphan Drug Designation for Hereditary Angioedema
source: shutterstock.com

Investigational Therapy Earns Orphan Drug Designation for Hereditary Angioedema

According to a story from Business Wire, the biopharmaceutical company Astria Therapeutics, Inc., recently announced that its experimental therapy navenibart has earned the US Food and Drug Administration's Orphan Drug…

Continue Reading Investigational Therapy Earns Orphan Drug Designation for Hereditary Angioedema
Study: Tirzepatide Lowers Risk of Pancreatitis and Diabetic Retinopathy vs GLP-1s
source: shutterstock.com

Study: Tirzepatide Lowers Risk of Pancreatitis and Diabetic Retinopathy vs GLP-1s

According to a story from Healio, analysis of the FDA Adverse Events Reporting System database indicates that tirzepatide has a superior safety profile when compared to GLP-1 inhibitors that have…

Continue Reading Study: Tirzepatide Lowers Risk of Pancreatitis and Diabetic Retinopathy vs GLP-1s
NDA for NF1-PN Treatment Charges Ahead with Priority Review
source: shutterstock.com

NDA for NF1-PN Treatment Charges Ahead with Priority Review

According to a press release from GlobeNewswire, the biopharmaceutical company SpringWorks Therapeutics recently announced that the US Food and Drug Administration (FDA) has granted the company's New Drug Application (NDA)…

Continue Reading NDA for NF1-PN Treatment Charges Ahead with Priority Review
Study: 77% of Pregnancies Result in Live Births After Stem Cell Transplant
source: shutterstock.com

Study: 77% of Pregnancies Result in Live Births After Stem Cell Transplant

Women who undergo allogeneic hematopoietic cell transplantation (alloHCT) face significant treatment-related challenges regarding fertility. However, science seems to be overcoming many treatment-related fertility challenges after alloHCT and successful pregnancies are…

Continue Reading Study: 77% of Pregnancies Result in Live Births After Stem Cell Transplant
Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD
source: shutterstock.com

Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD

The COURSE Phase IIa clinical trial was conducted to evaluate tezepelumab (marketed as TEZSPIRE) in people living with chronic obstructive pulmonary disease (COPD) that had a wide range of blood…

Continue Reading Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD
Why Dr. Fiorentino Believes in a Promising Treatment Future for Dermatomyositis
https://unsplash.com/photos/tWTFjznQlBA

Why Dr. Fiorentino Believes in a Promising Treatment Future for Dermatomyositis

In some cases, dermatomyositis can be difficult to treat. A variety of treatment options are available, from corticosteroids and immunosuppressants to antimalarials, colchicine, alendronate, and warfarin. But this rare condition…

Continue Reading Why Dr. Fiorentino Believes in a Promising Treatment Future for Dermatomyositis
Positive Results from the Phase 3 Trial of ANX005 in Guillain-Barré Syndrome
source: shutterstock.com

Positive Results from the Phase 3 Trial of ANX005 in Guillain-Barré Syndrome

The long-awaited positive results of Annexon Inc.’s Phase 3 trial investigating ANX005 for Guillain-Barré syndrome (GBS) was presented at the PNS 2024 Annual Meeting. Several leading global GBS experts spoke…

Continue Reading Positive Results from the Phase 3 Trial of ANX005 in Guillain-Barré Syndrome
These Nonprofits Just Shelled Out $5.2 Million to Fund An Experimental Parkinson’s Drug
source: shutterstock.com

These Nonprofits Just Shelled Out $5.2 Million to Fund An Experimental Parkinson’s Drug

According to a story from PR Newswire, the biotech company Mission Therapeutics was just awarded $5.2 million in funding to support MTX325, the company's investigational Parkinson's disease therapy. Intended to…

Continue Reading These Nonprofits Just Shelled Out $5.2 Million to Fund An Experimental Parkinson’s Drug